These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 16564690

  • 1. Evaluation of imatinib mesylate effects on glioblastoma aggressiveness with SPECT radiotracer 99mTc-(v)-DMSA.
    Le Jeune N, Dubois F, Bin V, Perek N.
    Eur J Cancer; 2006 May; 42(8):1004-13. PubMed ID: 16564690
    [Abstract] [Full Text] [Related]

  • 2. Human glioblastoma and carcinoma xenograft tumors treated by combined radiation and imatinib (Gleevec).
    Oertel S, Krempien R, Lindel K, Zabel A, Milker-Zabel S, Bischof M, Lipson KE, Peschke P, Debus J, Abdollahi A, Huber PE.
    Strahlenther Onkol; 2006 Jul; 182(7):400-7. PubMed ID: 16826359
    [Abstract] [Full Text] [Related]

  • 3. Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment.
    Razis E, Selviaridis P, Labropoulos S, Norris JL, Zhu MJ, Song DD, Kalebic T, Torrens M, Kalogera-Fountzila A, Karkavelas G, Karanastasi S, Fletcher JA, Fountzilas G.
    Clin Cancer Res; 2009 Oct 01; 15(19):6258-66. PubMed ID: 19789313
    [Abstract] [Full Text] [Related]

  • 4. Pentavalent technetium-99m dimercaptosuccinic acid [99m Tc-(V)DMSA] brain scintitomography--a plausible non-invasive depicter of glioblastoma proliferation and therapy response.
    Tsiouris S, Pirmettis I, Chatzipanagiotou T, Ptohis N, Papantoniou V.
    J Neurooncol; 2007 Dec 01; 85(3):291-5. PubMed ID: 17554495
    [Abstract] [Full Text] [Related]

  • 5. Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor.
    Holdhoff M, Kreuzer KA, Appelt C, Scholz R, Na IK, Hildebrandt B, Riess H, Jordan A, Schmidt CA, Van Etten RA, Dörken B, le Coutre P.
    Blood Cells Mol Dis; 2005 Dec 01; 34(2):181-5. PubMed ID: 15727903
    [Abstract] [Full Text] [Related]

  • 6. Platelet-derived growth factor receptors: a therapeutic target in solid tumors.
    George D.
    Semin Oncol; 2001 Oct 01; 28(5 Suppl 17):27-33. PubMed ID: 11740804
    [Abstract] [Full Text] [Related]

  • 7. Influence of Pi3-K and PKC activity on 99mTc-(V)-DMSA uptake: correlation with tumour aggressiveness in an in vitro malignant glioblastoma cell line model.
    Le Jeune N, Perek N, Dubois F.
    Eur J Nucl Med Mol Imaging; 2006 Oct 01; 33(10):1206-13. PubMed ID: 16763818
    [Abstract] [Full Text] [Related]

  • 8. The platelet-derived growth factor receptor as a target for vascular endothelial growth factor-mediated anti-angiogenetic therapy in head and neck cancer.
    Bran B, Bran G, Hörmann K, Riedel F.
    Int J Oncol; 2009 Jan 01; 34(1):255-61. PubMed ID: 19082496
    [Abstract] [Full Text] [Related]

  • 9. Differential effect of imatinib and synergism of combination treatment with chemotherapeutic agents in malignant glioma cells.
    Ren H, Tan X, Dong Y, Giese A, Chou TC, Rainov N, Yang B.
    Basic Clin Pharmacol Toxicol; 2009 Mar 01; 104(3):241-52. PubMed ID: 19159435
    [Abstract] [Full Text] [Related]

  • 10. Imatinib-induced regression of AIDS-related Kaposi's sarcoma.
    Koon HB, Bubley GJ, Pantanowitz L, Masiello D, Smith B, Crosby K, Proper J, Weeden W, Miller TE, Chatis P, Egorin MJ, Tahan SR, Dezube BJ.
    J Clin Oncol; 2005 Feb 10; 23(5):982-9. PubMed ID: 15572730
    [Abstract] [Full Text] [Related]

  • 11. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
    Distler JH, Jüngel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RE, Michel BA, Hauser T, Schett G, Gay S, Distler O.
    Arthritis Rheum; 2007 Jan 10; 56(1):311-22. PubMed ID: 17195235
    [Abstract] [Full Text] [Related]

  • 12. Platelet-derived growth factor receptor antagonist STI571 (imatinib mesylate) inhibits human vascular smooth muscle proliferation and migration in vitro but not in vivo.
    Hacker TA, Griffin MO, Guttormsen B, Stoker S, Wolff MR.
    J Invasive Cardiol; 2007 Jun 10; 19(6):269-74. PubMed ID: 17541129
    [Abstract] [Full Text] [Related]

  • 13. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C, Zieher H, Roth A, Hauser K, Lipson KE, Weber KJ, Debus J, Abdollahi A, Huber PE.
    Clin Cancer Res; 2008 Apr 01; 14(7):2210-9. PubMed ID: 18381963
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of tyrosine kinases PDGFR and C-Kit by imatinib mesylate interferes with postnatal testicular development in the rat.
    Nurmio M, Toppari J, Zaman F, Andersson AM, Paranko J, Söder O, Jahnukainen K.
    Int J Androl; 2007 Aug 01; 30(4):366-76; discussion 376. PubMed ID: 17705809
    [Abstract] [Full Text] [Related]

  • 15. Chronic allograft nephropathy is prevented by inhibition of platelet-derived growth factor receptor: tyrosine kinase inhibitors as a potential therapy.
    Savikko J, Taskinen E, Von Willebrand E.
    Transplantation; 2003 Apr 27; 75(8):1147-53. PubMed ID: 12717194
    [Abstract] [Full Text] [Related]

  • 16. Oral imatinib mesylate (STI571/gleevec) improves the efficacy of local intravascular vascular endothelial growth factor-C gene transfer in reducing neointimal growth in hypercholesterolemic rabbits.
    Leppänen O, Rutanen J, Hiltunen MO, Rissanen TT, Turunen MP, Sjöblom T, Brüggen J, Bäckström G, Carlsson M, Buchdunger E, Bergqvist D, Alitalo K, Heldin CH, Ostman A, Ylä-Herttuala S.
    Circulation; 2004 Mar 09; 109(9):1140-6. PubMed ID: 14769706
    [Abstract] [Full Text] [Related]

  • 17. Amelioration of liver fibrogenesis by dual inhibition of PDGF and TGF-beta with a combination of imatinib mesylate and ACE inhibitor in rats.
    Yoshiji H, Kuriyama S, Noguchi R, Ikenaka Y, Yoshii J, Yanase K, Namisaki T, Kitade M, Yamazaki M, Asada K, Akahane T, Tsujimoto T, Uemura M, Fukui H.
    Int J Mol Med; 2006 May 09; 17(5):899-904. PubMed ID: 16596278
    [Abstract] [Full Text] [Related]

  • 18. The effect of imatinib mesylate (Glivec) on human tumor-derived cells.
    Knight LA, Di Nicolantonio F, Whitehouse PA, Mercer SJ, Sharma S, Glaysher S, Hungerford JL, Hurren J, Lamont A, Cree IA.
    Anticancer Drugs; 2006 Jul 09; 17(6):649-55. PubMed ID: 16917210
    [Abstract] [Full Text] [Related]

  • 19. Progesterone sensitizes breast cancer MCF7 cells to imatinib inhibitory effects.
    Rocha A, Azevedo I, Soares R.
    J Cell Biochem; 2008 Feb 01; 103(2):607-14. PubMed ID: 17614352
    [Abstract] [Full Text] [Related]

  • 20. AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate.
    Shaw TJ, Vanderhyden BC.
    Gynecol Oncol; 2007 Apr 01; 105(1):122-31. PubMed ID: 17169414
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.